Results 111 to 120 of about 21,331 (226)

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

open access: yesAddiction, Volume 121, Issue 5, Page 1272-1289, May 2026.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring   +8 more
wiley   +1 more source

Genetic Association of Sexual Behavior, Sildenafil, and Hormonal Contraceptives With Mental Disorders. [PDF]

open access: yesCNS Neurosci Ther
Lin Z   +10 more
europepmc   +1 more source

Report on NSP

open access: yes
Reports on the National Label Pack A+ label stakeholders Platform (NSP) meetingsDescription: 6 pdf files, 1 per country, 1 page summary in EN, document in national languages, to be submitted by all National pilot responsibles (AT, FR, DE, IT, PT, UK). First report on month 13 and final report on month 25.
openaire   +1 more source

Predictors of outpatient treatment engagement following a visit to a specialized emergency department for substance use: A cohort study using high‐resolution electronic health records

open access: yesAddiction, Volume 121, Issue 5, Page 1237-1248, May 2026.
Abstract Background and aims Substance‐related emergency department (ED) visits represent a critical opportunity to link individuals with sustained treatment for substance use disorders (SUD), yet few transition to post‐acute treatment. Among emerging initiatives to integrate specialized SUD care into ED services, the Stockholm SUD‐ED is an example of ...
Danilo Romero   +5 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

O consumo de NSP em Portugal

open access: yes, 2018
Novas Substâncias Psicoativas (NSP) representam um grupo de substâncias que tem crescido rapidamente e cujos mercados têm beneficiado do desenvolvimento tecnológico. EMCDDA define-as como “substâncias naturais ou sintéticas que não são controladas pelos organismos oficiais e frequentemente visam mimetizar os efeitos das substâncias controladas”.
Henriques, S., Silva, J. P.
openaire   +3 more sources

A Highly Conserved SNARE‐Associated Protein Enhances Plant Immunity by Regulating Vesicle Trafficking

open access: yesPlant Biotechnology Journal, Volume 24, Issue 5, Page 3426-3440, May 2026.
ABSTRACT The plant endomembrane system and vesicle trafficking are central to plant immunity, mediating the targeted delivery and recycling of defence molecules during pathogen attack. Here, we investigated the functional role of soybean Vacuole Membrane Protein 1 (GmVMP1) in mediating resistance against soybean cyst nematode (SCN, Heterodera glycines).
Tracy E. Hawk   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy